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(OR:1.16; CI:1.03–1.31), and 2 (OR:1.47; CI:1.30–1.65)]. Findings were similar
when stratifying the sample by age group. CONCLUSIONS: Findings suggest that a 
quarterly assessment of SABA utilization can be used to identify patients at risk for
asthma-related exacerbations. The incidence of an asthma exacerbation was associated
with greater SABA use in the previous quarter.
RR2
HEALTH CARE UTILIZATION AND COST OF COPD IN A MEDICAID
POPULATION: THE ROLE OF CO–MORBID CONDITIONS
Lin PJ, Shaya FT
University of Maryland, Baltimore, MD, USA
OBJECTIVES: Comorbidities in patients with chronic obstructive pulmonary disease
(COPD) are associated with higher mortality, hospitalization, and poor quality of life. 
The objectives of this study were to characterize a comprehensive comorbidity proﬁ le 
among COPD patients, and to explore the impact of comorbidities on medical utiliza-
tion and cost in a low-income Medicaid population. METHODS: This retrospective 
cohort study analyzed medical claims from the Maryland Medicaid database. We
employed a 1:2 case-control design to select 1388 COPD patients aged 40 to 64 years 
with at least 24 months of continuous enrollment and 2776 demographically-matched
controls without COPD. Logistic regressions were performed to calculate odds ratios
that compared differences in the prevalence of comorbidities, including 17 conditions
deﬁ ned by the Charlson Comorbidity Index (CCI) and 6 additional conditions known 
to coexist with COPD. Generalized linear models were performed to estimate the
average medical utilization and cost by speciﬁ c comorbidity. RESULTS: Medicaid 
COPD patients had more comorbidities compared with non-COPD controls (CCI 
score  1.56 vs. 1.37, p  0.004), and were more likely to have myocardial infarction,
congestive heart failure, cerebrovascular disease, peptic ulcer, mild liver disease, hyper-
tension, sleep apnea, tobacco use, and edema. COPD patients on average had 16 more 
medical claims (81.4 vs. 65.4, p  0.001) and incurred $1871 higher medical cost per
year than non-COPD controls ($7603 vs. $5732, p  0.001). Ten out of the 17 condi-
tions deﬁ ned by the CCI as well as hypertension, tobacco use, and edema were associ-
ated with the excess medical utilization and cost in COPD patients. Depression was
associated with excess medical utilization but not cost. CONCLUSIONS: Medicaid
COPD patients have a substantial burden of comorbidities, which translate into higher
medical utilization and cost. Effective disease management and treatment protocols
are needed to reduce co-morbidity burden.
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USE OF HEALTH CARE SERVICES IN PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATED WITH 
BUDESONIDE/FORMOTEROL VIA DRY POWDER INHALER
(BUD/FM DPI) VERSUS TIOTROPIUM DPI
Blais L1, Forget A2, Ramachandran S3
1Université de Montréal, Montreal, QC, Canada, 2Hôpital du Sacré-Coeur de Montréal, 
Montréal, QC, Canada, 3AstraZeneca LP, Wilmington, DE, USA
OBJECTIVES: To assess real-world effectiveness of BUD/FM DPI versus tiotropium
DPI in COPD patients METHODS: Data from the Quebec health care databases
were used to construct a matched cohort of COPD patients aged d40 years newly
treated with BUD/FM DPI or tiotropium DPI from 2003–2007. Patients were matched 
on age, sex, COPD exacerbations (short-course prescription of oral corticosteroids
[OCSs], emergency department [ED] visits or hospitalizations for COPD; d2 events
occurring within 15 days counted as 1 exacerbation), and use of short-acting
inhaled a]2-agonists (SABAs) and ipratropium in the year before therapy began. 
The number of exacerbations, ED visits, and hospitalizations for COPD; claims
for OCS prescriptions; and the average weekly doses (dose  2 inhalations) of 
SABAs and ipratropium were compared for BUD/FM DPI versus tiotropium DPI 
users for a 1-year post-therapy period. Poisson and linear regression models were used
to produce adjusted rate ratios (RR) and mean differences (MD). RESULTS: Of 
981 BUD/FM DPI and 981 tiotropium DPI users in the cohort, 78% were aged „d 
65 years and 53% were men. No signiﬁ cant differences were seen for COPD exacerba-
tions (RR  0.94; 95% CI, 0.77–1.15), ED visits for COPD (RR  0.80; 95% CI,
0.54–1.20), and claims for OCS prescriptions (RR  0.93; 95% CI, 0.72–1.21) 
between BUD/FM DPI and tiotropium DPI users in the year after the start of 
therapy. However, BUD/FM DPI users had signiﬁ cantly fewer hospitalizations for
COPD (RR  0.65; 95% CI, 0.44–0.97), used less SABAs (MD  0.48; 95% CI,
0.67 to 0.28), and used more ipratropium (MD  0.35; 95% CI, 0.21–0.50).
CONCLUSIONS: These ﬁ ndings showed that patients using BUD/FM DPI were sig-
niﬁ cantly less likely to have COPD exacerbations leading to a hospitalization, but as 
likely as tiotropium DPI users to require emergency care or OCS therapy in the year 
after initiation of therapy.
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OUTCOMES ASSOCIATED WITH TIOTROPIUM USE IN COPD PATIENTS
Lee TA1, Wilke CT2, Joo M3, Stroupe KT4, Krishnan JA5, Schumock GT2, Pickard AS2
1Hines VA Hospital and Northwestern University, Chicago, IL, USA, 2College of Pharmacy, 
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OBJECTIVES: To date, there is mixed evidence on the safety and effectiveness of 
tiotropium. Our objective was to evaluate the comparative effectiveness of regimens
containing tiotropium versus other medication regimens for chronic obstructive pul-
monary disease (COPD) in real-world clinical settings. METHODS: We conducted a 
cohort study on two separate cohorts with a diagnosis of COPD in the VA health care 
system. Patients with a COPD diagnosis prescribed tiotropium and patients in a his-
toric cohort prior to the introduction of tiotropium were selected for comparison using
propensity scores, with the base case including scores from 0.1 to 0.4. Outcomes
identiﬁ ed during follow-up were all-cause mortality, COPD exacerbations, and
COPD hospitalizations. Exposure to COPD medication regimens was deﬁ ned in a
time-varying manner and Cox proportional hazards regression were employed to
evaluate outcomes. RESULTS: For 42,090 patients in the base case, the regimen of 
tiotropium plus inhaled corticosteroids plus long-acting beta-agonists was associated 
with 40% reduced risk of death (HR  0.60 [95% CI 0.45, 0.79]) compared to inhaled
corticosteroids plus long-acting beta-agonists. This combination was also associated 
with reduced rates of COPD exacerbations (HR  0.84 [0.73, 0.97]) and COPD hos-
pitalizations (HR  0.78 [0.62, 0.98]). Tiotropium in combination with other medica-
tion regimens was associated with increased risk of events compared to inhaled 
corticosteroids plus long-acting beta-agonists. CONCLUSIONS: When used with 
inhaled corticosteroids and long-acting beta-agonists, tiotropium use was associated 
with a decreased risk of mortality compared to treatment with inhaled corticosteroids
and long-acting beta-agonists. However, this result was not consistent in other medica-
tion regimens that included tiotropium.
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PMC1
CLASSIFYING PATIENTS WITH METABOLIC SYNDROME USING THE
LATENT CLASS ANALYSIS (LCA)
Liu G1, Luo N2, McCollam PL3
1Peking University, Beijing, China, 2National University of Singapore, Singapore, Singapore, 3Eli
Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To identify subgroups of metabolic syndrome patients who would
be more homogeneous in terms of metabolic risk factors. METHODS: The 
electronic medical record database from GE Healthcare was used for this study. The 
database comprises de-identiﬁ ed longitudinal medical records of nationally repre-
sentative patients attending general practitioners. All adult patients were assessed 
for the presence of metabolic syndrome using the guidelines proposed by the 
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). 
A latent class analysis was conducted based on the abnormality of patients’ metabolic 
risk factors including triglycerides (TG; q150 mg/dL), high-density lipoprotein 
cholesterol (HDL-C; men: 40 mg/dL; women: 50 mg/dL), blood pressure (BP; sys-
tolic q130 mmHg, diastolic q85 mmHg, or drug treatment for hypertension), fasting
plasma glucose (q100 mg/dL or drug treatment for diabetes mellitus), and waist cir-
cumference (WC; men: q102 cm; women: q88 cm). The ﬁ nal model was selected based 
on model ﬁ t indices including Akaike’s information criterion, Bayesian information 
criterion (BIC), and sample-size adjusted BIC. RESULTS: Metabolic syndrome was 
present in 19,251 individuals. The prevalence of high blood pressure was 96.4%. All 
the ﬁ t indices in the LCA modeling pointed to a 5-class solution. In addition to high 
blood pressure, members of Class 1 (6.5%) had abnormal TG and HDL-C; members 
of Class 2 (4.6%) had abnormal HDL-C and WC; members of Class 3 (19.7%) had 
abnormal TG and WC and the majority also had abnormal HDL-C (probability: 
68.7%); members of Class 4 (8.2%) had abnormal plasma glucose and WC; and
members of Class 5 (61.1%) had high probability of abnormality in all metabolic risk 
factors (range: 79.9–100%). CONCLUSIONS: LCA represents a new method for 
casemix study of patients with metabolic syndrome. The subgroups of metabolic syn-
drome identiﬁ ed in this study need to be further studied for its usefulness in clinical
and health services research.
PMC2
LONGITUDINAL DATA EXPLORATION WITH STACKED CUMULATIVE
PERCENT PLOTS FOR CATEGORICAL DATA
Gilligan TM, Hill CD
RTI Health Solutions, Research Triangle Park, NC, USA
Longitudinal clinical trial data present analysts with the unique challenge of summariz-
ing large trends over time without losing the detail of changes from one timepoint 
to the next. Analysts must ﬁ nd a balance between the preservation of details at
each timepoint and parsimonious output that can be easily summarized and inter-
preted. For instruments that measure outcomes using nominal or ordinal response 
categories, analysts may want to preserve categorical information by reporting
response category frequencies over time. In this case, the frequency of change across
the course of treatment or disease progression is more informative, and perhaps more
appropriate, than mean or median change. Collapsing responses into mean or medians 
draws attention to overall trends, while losing the ability to detect movement from
one category response to another. A novel data visualization solution, stacked cumula-
tive percent plots, allows analysts to retain individual categorical responses and 
track the movement of categorical responses over time. Comparisons of stacked 
cumulative percent plots with mean plots illustrate the additional information that 
can be learned from retaining categorical information. Further, a variation of the 
proposed plot allows analysts to visualize the frequency of response category changes 
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from timepoint to timepoint. Stacked cumulative percent plots can be applied to 
diverse disease types and to outcomes with varying amounts of anticipated change 
from timepoint to timepoint.
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USING FRONTIER ANALYSIS TO OPTIMIZE THE OVERALL LIFE YEARS
GAINED IN VACCINATION POLICY OF INFECTIOUS DISEASES
Chang CJ1, Wu D2, Lin YJ1, Fann CS3
1Chang Gung University, Tao Yuan, Tao Yuan, Taiwan, 2National Yang-Ming University, Taipei, 
Taiwan, 3Academia Sinica, Taipei, Taiwan
OBJECTIVES: The aim of the study is to utilize the novel frontier analysis to 
search for optimal strategy of vaccination policy against infectious diseases with
limited vaccine supply. METHODS: An important goal of public health research 
is to predict clinical impact by nation-wide mass vaccination in preventing infectious 
diseases. Vaccination is usually given across potential vulnerable populations such 
as children. However, due to limited resources provided by the government among
a growing number of competing vaccine products, some vaccinations are to be given
to some targeted high-risk cohorts against infectious diseases, such as pneumonia 
or inﬂ uenza. Hence, the optimal strategy of vaccination policy for effective disease 
control becomes a practical concern. We propose a model using frontier analysis 
to seek the optimal vaccination policy in controlling infectious disease epidemics
with limited resources. The problem is initially formulated to ﬁ nd the maximal life 
years gained while minimizing the variance. Various vaccination policies were
explored in ﬁ nding the optimal vaccination strategy. The indirect effects on unvacci-
nated cohorts were also considered in the analysis. The technique is illustrated using 
pneumococcal conjugate vaccine (PCV) in Taiwan as an example. RESULTS: Using
the empirical study of PCV and various scenarios of the policy with limited resource,
we provide the best vaccination strategy among various deﬁ ned cohorts and report
the maximal life years gained with the ﬁ xed total cost of the vaccine given. Our study
can be generalized to the optimization of vaccination strategies for most infectious 
diseases among different population structures. CONCLUSIONS: When disease
burden is high, more emphasis should be laid on the possible health beneﬁ ts gained
with a vaccination program, instead of just considering the economic beneﬁ ts. Our
study can help to guide decision makers in determining optimal uses of limited
quantities of vaccine across multiple targeted cohorts to effectively control infectious
diseases.
PMC4
A FRAMEWORK FOR DEVELOPING A FLEXIBLE CONTROL–BASED
ASTHMA POLICY MODEL
Campbell JD1, Hansen RN1, Briggs A2, Sullivan SD1
1University of Washington, Seattle, WA, USA, 2University of Glasgow, Glasgow, UK
OBJECTIVES: The goal of asthma management is to gain and maintain control. 
Several validated patient-reported measures are available to assess the degree of 
control: Asthma Control Questionnaire (ACQ), Asthma Control Test (ACT), and the 
Asthma Therapy and Assessment Questionnaire (ATAQ). We propose a ﬂ exible and 
transparent model structure that represents disease variability through exacerbation
rates and any one of the three control instruments. METHODS: We developed a 
Markov model to simulate cohorts transitioning among six health states: an asthma 
control continuum state (variability in control is tracked using one of the three control 
instruments), three severity levels of asthma exacerbation, and asthma and non-asthma
related death. To estimate the cost and outcome weights for the control continuum 
state, we explored the relationship between the ATAQ (higher ATAQ  less control) 
and management costs (including absenteeism costs) and utilities using a large asthma
registry of exacerbation-free patients. A hypothetical asthma intervention added to 
standard-of-care was compared to standard-of-care alone as summarized by the fol-
lowing product proﬁ le: a 50% reduction in asthma exacerbation rates, a 0.5 absolute
improvement in the ATAQ score, and an additional $10,000 per annum intervention 
cost. RESULTS: The estimated change in bi-weekly asthma management costs for a 
one unit increase in the ATAQ score was $36.12 (robust SE  $3.95) and for utilities
was 0.05 (robust SE  0.0041). Assuming a ﬁ ve year time horizon, the hypothetical 
intervention plus standard-of-care had an incremental mean cost of $25,800 (95% 
interval $10,600, $41,000), quality adjusted life year (QALY) of 0.257 (0.106, 0.435), 
and cost per QALY of $100,500/QALY ($13,700, $199,800). CONCLUSIONS: As 
relationships emerge between any of the instruments of control and costs and utilities,
this versatile model can forecast: long-term burden of disease, value of existing and
emerging interventions, and inputs that yield the highest return from further study.
PMC5
PRO AND UTILITY ASSESSMENT: ADDRESSING CONFOUNDS OF 
CHANGING SELF–REFERENCE
Pashko S
Omnicare Clinical Research, King of Prussia, PA, USA
Identity, the view of self-reference, is not static across populations and is probably not
stable within an individual over time. Philosophers, psychologists and the religious
continue to offer support for particular points of view of identity but there are many 
differences among them. These differences seem quite able to bias utility and patient-
reported outcomes assessments. As such, care must be taken to understand the self-
reference schemas of the population within which self-assessments are validated and
used. Some of the options people have and use for self-reference are: 1. operational
(e.g., I am a clinical researcher or a father), 2. preference-oriented (e.g., I am a lover 
of wine or a “runner”), 3. physical (e.g., I am my body), 4. psychological (e.g., I am 
my ego), 5. religious (e.g., I am spirit) and 6. philosophical (e.g., I am thinking, I am
consciousness, no such thing as identity exists, I am subjective experience). It’s surpris-
ing self-assessments are conducted when we don’t know who is responding to our
questions. The confound of identity is important to study in its own right because of 
how strongly it can inﬂ uence public policy through research ﬁ ndings based on self-
assessments. “View of self-reference” seems a fundamental and necessary element for
inclusion into requirements for construction and validation of PROs. Otherwise, 
instrument bias could be speciﬁ cally used to make a certain claim, much like regression 
towards the mean could be used if it was not previously identiﬁ ed as a threat to valid-
ity. That identify may shift over time within an individual, say from an external focus 
to an internal focus, may be the reason why some terminally ill patients report good 
quality of life despite their poor health. When the body is not a factor in one’s identity, 
what is the meaningfulness of health-related quality of life anyway?
PMC6
META–REGRESSION AS A METHOD OF IDENTIFICATION OF THE
CAUSES OF HETEROGENEITY BETWEEN STUDIES ON THE EXAMPLE
OF RELATIONSHIP BETWEEN SURROGATES AND CLINICALLY
IMPORTANT ENDPOINTS IN TYPE–2 DIABETES MELLITUS
Marcisz A1, Rys P2, Wieczorek A1, Plisko R2, Wladysiuk M1, Skrzekowska-Baran I3
1HTA Consulting, Krakow, Malopolska, Poland, 2HTA Consulting, Krakow, Poland, 3Novo 
Nordisk, Inc., Warsaw, Mazowieckie, Poland
OBJECTIVES: Use of meta-regression to explain heterogeneity between the studies
evaluating relationship between the level of glycated hemoglobin (HbA1c) and the risk 
of development of retinopathy in patients with type 2 diabetes mellitus (DMT2). In 
meta-regression the results of the studies under consideration are treated as points to 
be analyzed by weighted regression. If the results obtained in a model without covari-
ates indicate heterogeneity of studies, then inclusion of subsequent covariates into the
model can make it possible to check if speciﬁ c variables explain heterogeneity. The
amount of heterogeneity may be expressed as between-study variance. If between-
study variance decreases after inclusion of a speciﬁ c covariate into the model, it means
that heterogeneity between the studies may be explained by that covariate. METHODS:
The following covariates were considered: observation period, type of the study, 
sample size, HbA1c level, age, duration of DMT2, BMI, cholesterol level, arterial
blood pressure. Due to a scarce number of studies available between-study variance 
was estimated using the REML method. The value of between-study variance evalu-
ated using a meta-regression model for retinopathy in DMT2 without covariates was 
0.4547. RESULTS: Inclusion of the difference between the intervention group and the
control group with respect to the HbA1c level resulted in decrease to 0.1572. There-
fore the covariate under consideration explains the heterogeneity in 65.4%. The 
obtained value of directional coefﬁ cient was statistically signiﬁ cant and equal to
0.5824, which means that increase of difference between the groups with HbA1c level 
by 1 unit results in increase of the logarithm of relative risk by 0.5824, reﬂ ecting 
increase the risk by 1.79 times. CONCLUSIONS: It was demonstrated using meta-
regression that the difference with respect to the HbA1c level is the cause of hetero-
geneity between the studies. Relative risk of development of retinopathy increases with 
increase of the difference in HbA1c level.
PMC7
EFFECTS OF HETEROGENEITY ON THE ESTIMATION AND 
COMPARISON OF MEDICATION ERROR RATES
de Moor C, Golembesky A
PPD Inc, Morrisville, NC, USA
OBJECTIVES: The clinical consequences and costs of medication errors (ME) have
signiﬁ cant implications on quality of care. A detailed understanding of the occurrence 
and patterns of MEs is critical to reducing ME rates and improving patient outcomes.
However, ME rates are often estimated inaccurately. ME rates are typically heteroge-
neous with respect to hospitals and units within hospitals, because of differences in 
health care provider (HCP) experience and skill. Although this heterogeneity has 
important implications for the precision and power of ME analysis, it is seldom taken
into account in the estimation of MEs. METHODS: To evaluate the effects of hetero-
geneity on the precision and power of estimated ME rates, we assumed three sources 
of heterogeneity: hospital, unit (or HCP) within hospital, and random error. We 
derived formulas representing the variances of the estimated ME rates and the vari-
ances of comparisons of ME rates, and graphically illustrated the effects of sample
sizes and magnitude of heterogeneity on the variances. RESULTS: The heterogeneity
associated with hospital and unit induces clustering of MEs within hospitals and units, 
increasing variability in the estimated ME rates compared with what would be 
observed in the absence of heterogeneity. Even in the presence of low levels of hetero-
geneity, the variances of the estimated ME rates can be substantially increased. Power 
associated with comparisons of ME rates also can be substantially affected with 
decreased power for comparisons between hospitals or units and increased power for 
comparisons within hospitals or units. CONCLUSIONS: Heterogeneity of MEs with 
respect to hospitals and hospital units (or HCPs) can have a substantial effect on preci-
sion and power, and should be incorporated in the analyses ME rates. We provide 
precision and power formulas for planning future studies of MEs.
